[1]王丽娜,周慧敏,郭玉卿,等.α-硫辛酸联合依帕司他和甲钴胺治疗糖尿病神经源性膀胱的临床研究[J].国际内分泌代谢杂志,2014,(04):241-244.[doi:10.3760/cma.j.issn.1673-4157.2014.04.007]
　Wang Lina,Zhou Huimin,Guo Yuqing,et al.Clinical study of alpha-lipoic acid combined with epalrestat and mecobalamin on neurogenic bladder in patients with diabetes[J].International Journal of Endocrinology and Metabolism,2014,(04):241-244.[doi:10.3760/cma.j.issn.1673-4157.2014.04.007]
点击复制

α-硫辛酸联合依帕司他和甲钴胺治疗糖尿病神经源性膀胱的临床研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年04期
页码:
241-244
栏目:
论著
出版日期:
2014-08-31

文章信息/Info

Title:
Clinical study of alpha-lipoic acid combined with epalrestat and mecobalamin on neurogenic bladder in patients with diabetes
作者:
王丽娜; 周慧敏; 郭玉卿; 康岩; 刘璠
作者单位：050031　石家庄，河北医科大学第一医院内分泌科 　　
Author(s):
Wang Lina; Zhou Huimin; Guo Yuqing; Kang Yan; Liu Fan.
Department of Endocrinology，The First Hospital Affiliated to Hebei Medical University，Shijiazhuang 050031，China Corresponding author:Zhou Huimin，Email:zhouhuimindoctor@ 163.com
关键词:
糖尿病神经源性膀胱; 尿流动力学; 膀胱残余尿量; ?琢-硫辛酸; 依帕司他; 甲钴胺
Keywords:
Diabetic neurogenic bladder; Urodynamics; Residual urine volume of bladder; Alpha-lipoic acid; Epalrestat; Mecobalamin
DOI:
10.3760/cma.j.issn.1673-4157.2014.04.007
摘要:
目的　观察比较应用?琢-硫辛酸、依帕司他和甲钴胺单独或联合治疗糖尿病神经源性膀胱（DNB）的效果。方法　将DNB患者110例随机分为4组，?琢-硫辛酸联合依帕司他及甲钴胺治疗组（A组，n =25），?琢-硫辛酸联合甲钴胺治疗组（B组，n =35），依帕司他联合甲钴胺治疗组（C组，n =32），甲钴胺治疗对照组（D组，n =18），疗程为3周，3周后A、C组继续应用依帕司他至12周。治疗前及治疗后3周、12周B超测定膀胱残余尿量（RUV）及进行尿流动力学检查。结果　4组治疗后RUV较前均减少，差异有统计学意义（P ＜0.05）；A、B、C组治疗3周后膀胱初尿意容量（BS）均较治疗前减少，最大尿流率（MFR）、最大尿流率时逼尿肌压力（Pdet）增加，差异均有统计学意义（P 均＜0.05），其中A组RUV、BS改善程度较B组明显，B组较C组明显，其组间差异有统计学意义（P ＜0.05），治疗后3组间MFR、Pdet差异无统计学意义（P 均＞0.05），D组以上指标除RUV外治疗前、后变化无统计学意义（P 均＞0.05）；12周后4组RUV较治疗前差异仍有统计学意义（P ＜0.05），A组BS改善程度较B、C组明显，B组与C组比较差异无统计学意义（P 均＞0.05）；治疗3周后A组总有效率88.0%，B组85.7%，C组62.5%，D组50%，A、B两组之间疗效比较无统计学意义（P 均＞0.05），与C、D组疗效比较差异均有统计学意义（P ＜0.05）。结论　?琢-硫辛酸联合依帕司他、甲钴胺治疗DNB效果较好。
Abstract:
Objective　To observe the effects of alpha-lipoic acid alone or in combined with epalrestat and mecobalamin on diabetic neurogenic bladder. Methods　110 patients with diabetic neurogenic bladder were randomly divided into four groups，alpha-lipoic acid combined with epalrestat and mecobalamin group（group A， n =25），alpha-lipoic acid combined with mecobalamin group（group B，n =35）， epalrestat combined with mecobalamin group （group C，n =32） and mecobalamin group （group D，n =18）.After 3 weeks，group A and C were treated with epalrestat for another 9 weeks，and the other two groups discontinued the treatmeat. The residual urine volume of bladder（RUV） using B-ultralsound and urodynamic indices were tested at 0th，3th and 12th week. Results　After treatment， RUV of four groups decreased significantly（P ＜0.05）. The beginning of a sense of capacity（BS） in group A，B and C decreased significantly，pressure at maximum flow rate（Pdet） and the maximum flow rate（MFR） increased significantly（all P ＜0.05）.Compared with group B，RUV and BS decreased significantly in group A（all P ＜0.05）. Compared with group C，RUV and BS decreased significantly in B group（all P ＜0.05）. There were no significant change of MFR and Pdet among group A，B and C（all P ＞0.05）. There were no significant change of the urodynamic indices in group D before and after treatment（all P ＞0.05）. At the end of 12 weeks，RUV in all of groups were still improved compared with that before treatment. RUV and BS of group A were superior to group B and C.The effective rate in group A，B，C and D was 88.0%， 85.7%，62.5% and 50.0%，respectively. The effectiveness of group A and B were superior to group C and D，and there were no significant changes between A and B （all P ＞0.05）. Conclusion　Alpha-lipoic acid combined with epalrestat and mecobalamin has a better therapeutic effects on diabetic neurogenic bladder.

参考文献/References:

　[1]　黄克岭.老年女性膀胱颈梗阻伴糖尿病患者40例尿动力学分析[J].中国老年学杂志，2012，32（5）：1069-1070. 　
[2]　Chang S，Hypolite JA，Mohanan S，et al.Alteration of the PKC-mediated signaling pathway for smooth muscle contraction in obstruction-induced hypertrophy of the urinary bladder[J].Lab Invest， 2009，89（7）：823-832. 　
[3]　Donnan J，Ledger S.An update on the treatment and manage-ment of diabetic peripheral neuropathy[J].CANNT J，2007，16（4）：32-36. 　
[4]　Head KA.Peripheral neuropathy： pathogenic mechanisms and alternative therapies[J].Altern Med Rev，2006，11（4）：294-329. 　
[5]　常胜军. 硫辛酸治疗糖尿病周围神经病变疗效观察[J].实用神经疾病杂志，2009，12（19）：57-58. 　
[6]　章晓燕，刘芳，贾伟平.?琢-硫辛酸与糖尿病周围神经病变[J]. 国外医学内分泌学分册，2005，25（4）：262-264. 　
[7]　Shen B，Vetri F，Mao L，et al.Aldose reductase inhibition ame-liorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia[J].Brain Res，2010，1342（1342）：118-126. 　
[8]　Calderone V，Testai L，Martelli A，et al.Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts[J].J Pharm Pharmacol，2010，62（1）：107-113. 　
[9]　Gu J，Wang JJ，Yan J，et al.Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling[J].J Ethnopharmacol，2011，133（1）：6-13.
[10]　王云汉，杨进.糖尿病膀胱病研究进展[J].现代临床医学，2012， 38（2）：83-84.

备注/Memo

备注/Memo:
通信作者：周慧敏，Email:zhouhuimindoctor@163.com
更新日期/Last Update: 2014-07-20